Opiate Receptor Drugs – To Cycle or Not to Cycle Dosing? - Paul Anderson, NMD (2021 Conference) (LDN, low dose naltrexone)

Mast Cell Activation Syndrome (MCAS) - Leonard Weinstock, MD (2021 Conference) (LDN, low dose naltrexone)

Drug Resistant Depression - Elizabeth Livengood, NMD (2021 Conference) (LDN, low dose naltrexone)

Dr. Elizabeth Livengood’s presentation is on identifying different causes of depression, identifying depression, hyperthyroidism connections, identifying patient profiles who fit these descriptions, and understanding how to treat them. 

Hypothyroidism Variants - Elizabeth Livengood, NMD (2021 Conference) (LDN, low dose naltrexone)

History, Pharmacology and Mechanism - Stephen Dickson, BSC (hons) MRPharmS (2021 Conference) (LDN, low dose naltrexone)

LDN Research Trust 2021 Conference - Friday Morning

Ted Cole, DO - The Use of LDN and Amino Acids in Parkinson's Disease (2019 Conference) (LDN, low dose naltrexone)

Tara Thompson, PharmD - Compounding 101: The Basics of Compounding with Naltrexone (2019 Conference) (LDN, low dose naltrexone)

Tara Thompson, PharmD discusses the purpose of a compounding pharmacy, how to choose one, the benefits and limitations of compounding, and dosage forms. She give an overview of naltrexone, dosing of LDN in various conditions, and how to write a prescription for compounded naltrexone.

LDN 2019 Conference - Saturday Morning Q&A (2019 Conference) (LDN, low dose naltrexone)

Presentations on the below and questions were asked in relation to:

Sajad Zalzala, MD - What Patients Need to Know About Telemedicine (2019 Conference) (LDN, low dose naltrexone)

Sajad Zalzala, MD discusses what telemedicine is, its use and benefits, and about using LDN Direct telemedicine/LDN prescription business. Some telemedicine regulations are presented, as well as common conditions treated with LDN

Michael Ruscio, DC - The Gut-Thyroid Connection, Profound but Under-Appreciated (2019 Conference) (LDN, low dose naltrexone)